


IOCB AS CR




INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, v. v. i. PRAGUE

Scientific Activities of IOCB

The institute carries out fundamental research in organic chemistry, biochemistry and related disciplines, focusing in particular on medical and environmental applications. It educates graduate students. It is the seat of the Committee for defence of doctor of science dissertations in organic and bio-organic chemistry.

Research Areas — Medicinal Chemistry Biochemistry and Molecular Biology Organic Synthesis Chemistry of Natural Products Physical Chemistry Computational Chemistry



Prof.RNDr. Antonín Holý, DrSc., dr.hc.mult

The organic chemist Antonín Holý is one of the most successful Czech scientists. His most influential discoveries have yielded successful treatments for AIDS and type B viral hepatitis. His research deals with the chemistry of nucleic acid analogs and he lectures internationally. He directed the Institute for eight years. He holds over 60 patents and has co-authored 550 publications. His work has been cited more than 9,500 times.

He holds honorary degrees from Palacky Univerzity in Olomouc and from the Institute of Chemical Technology in Prague. He is Gilead

Professor in medicinal chemistry and Honorary Professor of The Univerzity of Manchester. He has received the EU Descartes Award for scientific research, and he is a member of the Learned Society of the Czech Republic.

Truvada

For use in combination with other HIV medications to treat HIV infections in adults. Truvada combines two HIV medications, Emtriva (emtricitabine) and Viread (tenofovir), into one pill that is taken once a day. It replaces 13 other tablets.

Vistide

Treats opportunistic diseases accompanying AIDS (gastric ulcers, herpes zoster, smallpox, viral inflammation of the eyes, etc.).

Hespera

Active against type B hepatitis. It is based on adefovir and has practically no side effects.

Viread

An antiviral drug for AIDS treatment which helps block reverse transcriptase – a special protein that is needed for HIV to replicate. By interfering with the replication process, Viread as part of combination therapy helps to lower viral load. The active compound is *tenofovir*.



Atripla

The first-ever once-daily single tablet regimen for HIV intended as a stand-alone therapy. The product combines Sustiva (efavirenz) and Truvada (emtricitabine and tenofovir). It replaces the vast number of pills that patients formally had to take.





manufactured by the Spofa

company.

